TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · major macro event coming up
HCM

HUTCHMED DRC

Healthcare · Drug Manufacturers - Specialty & Generic

14.20$ +0.0% vs. previous close Closing price · As of: Sep 29, 2026

Statements

Balance Sheet

HUTCHMED DRC (HCM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 1,753 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet HCM
Line item 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– 63 133 128 118 128 160 195 160 186 211 230 342 598 532 465 724 1,373 1,029 1,280 1,274 1,753
– 30 99 88 78 84 108 141 45 67 90 90 167 432 371 317 531 1,212 840 1,097 1,067 1,567
– 5.6 10 53 38 42 45 54 31 47 39 32 79 85 86 121 236 378 313 284 154 71
– 5.6 71 53 38 42 45 54 31 47 51 32 104 358 301 217 435 1,012 631 886 836 1,367
– 16 19 23 25 25 31 53 11 15 32 46 49 57 44 77 48 148 127 150 168 148
– 8.7 9.5 12 15 17 27 29 1.6 1.4 4.4 9.6 13 12 12 16 20 36 57 50 50 41
– – – – – – – – – 5.0 7.5 9.9 10.0 14 17 26 32 53 85 – – –
– – – – – – – 8.2 8.3 0.4 2.0 3.3 3.1 3.3 3.2 3.1 3.3 3.4 3.1 3.1 3.0 3.1
– 6.8 7.0 7.2 7.5 12 18 15 16 0.4 0.7 0.6 0.5 0.4 0.3 0.3 0.2 0.2 0.1 0.0 – 8.9
– 91 23 30 34 52 91 117 78 81 113 127 138 113 120 152 205 333 393 536 502 502
– 91 23 30 33 50 68 88 36 78 75 81 95 105 85 113 158 312 354 403 377 316
– 7.4 7.1 6.6 7.6 8.1 25 30 11 59 35 27 22 32 0.4 3.6 6.0 32 3.7 35 26 28
– 3.9 3.2 5.3 5.3 8.2 11 16 3.2 4.2 20 24 36 24 26 24 32 41 71 36 43 46
– – – – – – – – – – 30 27 27 0.0 27 27 27 0.0 18 48 59 68
– -34 103 90 75 66 60 65 71 89 39 83 184 462 389 288 484 987 610 731 760 1,238
– -34 -44 -60 -78 -87 -95 -94 -90 -74 -100 -92 -80 -107 -183 -290 -416 -610 -971 -871 -833 -379
102 73 91 102 102 102 103 105 105 106 106 109 120 123 133 133 28 159 169 174 175 175

Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?